Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Current Opinion in Urology|September 2, 2016
Cancer immunotherapy: new applications in urologic oncologyStephanie A Mullane, Joaquim BellmuntCurrent Opinion in Urology|February 25, 2016
Precision medicine for advanced prostate cancerStephanie A Mullane, Eliezer M Van AllenHematology/Oncology Clinics of North America|April 4, 2015
Perioperative therapy for muscle invasive bladder cancerJeffrey J Leow, André P Fay, Stephanie A Mullane, et al.Scientific Reports|June 11, 2016
Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial CarcinomaStephanie A Mullane, Lillian Werner, Jonathan Rosenberg, et al.Clinical Genitourinary Cancer|January 19, 2016
Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial CarcinomaStephanie A Mullane, Lillian Werner, Elizabeth A Guancial, et al.Plos One|June 4, 2015
Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial TumorsJoaquim Bellmunt, Lillian Werner, Jeffrey J Leow, et al.Urologic Oncology|September 1, 2015
Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010Alexander P Cole, Deepansh Dalela, Julian Hanske, et al.British Journal of Cancer|June 29, 2016
Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapyJoaquim Bellmunt, Chensheng Willa Zhou, Stephanie A Mullane, et al.Clinical Genitourinary Cancer|May 1, 2018
Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of ImmunotherapyGuru Sonpavde, Gregory Russell Pond, Jonathan E Rosenberg, et al.Cancer Medicine|February 28, 2015
HER2 as a target in invasive urothelial carcinomaJoaquim Bellmunt, Lillian Werner, Aristotle Bamias, et al.Pageof 2